ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Bioorganic & Medicinal Chemistry
Volume 14, Issue 23, 1 December 2006, Pages 7898-7909
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (553 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.bmc.2006.07.047    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2006 Elsevier Ltd All rights reserved.

Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs)

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Qiao-Hong Chena, P.N. Praveen Raoa and Edward E. KnausCorresponding Author Contact Information, a, E-mail The Corresponding Author

aFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alta., Canada T6G 2N8


Received 15 June 2006; 
revised 17 July 2006; 
accepted 26 July 2006. 
Available online 10 August 2006.

Abstract

A group of 4-(4-methanesulfonylphenyl)-3-phenyl-2(5H)furanones possessing an acetyl, 3-oxobut-1-ynyl, [hydroxyl(or alkoxy)imino]alkyl, [hydroxyl(or alkoxy)imino]alkynyl, and N-alkoxy(or N-phenoxy)carbonyl-N-hydroxy-N-ethylamino substituents at the para-position of the C-3 phenyl ring of rofecoxib were synthesized. This group of compounds was designed for evaluation as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs) that exhibit in vivo anti-inflammatory and analgesic activities. In vitro COX-1/COX-2, and 5-LOX/15-LOX, isozyme inhibition structure–activity relationships identified 3-[4-(1-hydroxyimino)ethylphenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (17a) having an optimal combination of COX-2 (COX-2 IC50 = 1.4 μM; COX-2 SI > 71), and 5-LOX and 15 LOX (5-LOX IC50 = 0.28 μM; 15-LOX IC50 = 0.32 μM), inhibitory effects. It was also discovered that 3-[4-(3-hydroxyiminobut-1-ynyl)phenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (18a) possesses dual COX-2 (IC50 = 2.7 μM) and 5-LOX (IC50 = 0.30 μM) inhibitor actions. Further in vivo studies employing a rat carrageenan-induced paw edema model showed that the oxime compounds (17a, 18a) were more potent anti-inflammatory agents than the 5-LOX inhibitor caffeic acid, and 15-LOX inhibitor nordihydroguaiaretic acid (NDGA), but less potent than the selective COX-2 inhibitor celecoxib. The results of this investigation showed that incorporation of a para-oxime moiety on the C-3 phenyl ring of rofecoxib provides a suitable template for the design of dual inhibitors of the COX and LOX enzymes.

Graphical abstract


Keywords: Rofecoxib analogues; 3,4-Diaryl-2(5H)furanones; Anti-inflammatory activity; Oximes; Dual cyclooxygenase and lipoxygenase inhibitors

Article Outline

1. Introduction
2. Chemistry
3. Results and discussion
4. Conclusions
5. Experimental
5.1. Ethyl 4-acetylphenylacetate (6)
5.2. Ethyl 4-(1-hydroxy)ethylphenylacetate (7)
5.3. 4-(1-Hydroxy)ethylphenylacetic acid (8)
5.4. 4-Iodophenylacetic acid (10)
5.5. 4-(3-Hydroxybut-1-ynyl)phenylacetic acid (11)
5.6. General procedure for the synthesis of 4-(4-methanesulfonylphenyl)-3-(4-substituted-phenyl)-2(5H)furanones (13 and 14)
5.6.1. 3-[4-(1-Hydroxy)ethylphenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (13)
5.6.2. 3-[4-(3-Hydroxybut-1-ynyl)phenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (14)
5.7. General procedure for the synthesis of 3-[4-acetyl and 4-(3-oxobut-1-ynyl)phenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanones (15 and 16)
5.7.1. 3-(4-Acetylphenyl)-4-(4-methanesulfonylphenyl)-2(5H)furanone (15)
5.7.2. 4-(4-Methanesulfonylphenyl)-3-[4-(3-oxobut-1-ynyl)phenyl]-2(5H)furanone (16)
5.8. General procedure for the synthesis of 3-(4-alkyloxyiminoalkylphenyl)-4-(4-methanesulfonylphenyl)-2(5H)furanones (17 and 18)
5.8.1. 3-[4-(1-Hydroxyimino)ethylphenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (17a)
5.8.2. 4-(4-Methanesulfonylphenyl)-3-[4-(1-methoxyimino)ethylphenyl]-2(5H)furanone (17b)
5.8.3. 3-[4-(1-Benzyloxyimino)ethylphenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (17c)
5.8.4. 3-[4-(3-Hydroxyiminobut-1-ynyl)phenyl]-4-(4- methanesulfonylphenyl)-2(5H)furanone (18a)
5.8.5. 4-(4-Methanesulfonylphenyl)-3-[4-(3-methoxyiminobut-1-ynyl)phenyl]-2(5H)furanone (18b)
5.8.6. 3-[4-(3-Benzyloxyiminobut-1-ynyl)phenyl]-4-(4- methanesulfonylphenyl)-2(5H)furanone (18c)
5.9. General procedure for the synthesis of N-alkoxycarbonyl-N-hydroxylamines (20)
5.9.1. N-Isopropyloxycarbonyl-N-{1-[4-(4-methanesulfonylphenyl)-2(5H)furanon-3-yl]phenyl}ethylhydroxylamine (20a)
5.9.2. N-Isobutyloxycarbonyl-N-{1-[4-(4-methanesulfonylphenyl)-2(5H)furanon-3-yl]phenyl}ethylhydroxylamine (20b)
5.9.3. N-Phenoxycarbonyl-N-{1-[4-(4-methanesulfonylphenyl)-2(5H)furanon-3-yl]phenyl}ethylhydroxylamine (20c)
5.9.4. N-Benzyloxycarbonyl-N-{1-[4-(4-methanesulfonylphenyl)-2(5H)furanon-3-yl]phenyl}ethylhydroxylamine (20d)
6. Molecular modeling (docking) study
7. In vitro lipoxygenase (LOX) inhibition assays
8. In vitro cyclooxygenase (COX) inhibition assay
9. Anti-inflammatory assay
10. Analgesic assay
Acknowledgements
References








Corresponding Author Contact InformationCorresponding author. Tel.: +1 780 492 5993; fax: +1 780 492 1217.

Bioorganic & Medicinal Chemistry
Volume 14, Issue 23, 1 December 2006, Pages 7898-7909
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.